Nil Albiol

It’s been a pleasure to share insights from our almost 10‑year #ARI0001 (var‑cel) program, tracing its development and compassionate use results, at the @tcddublin @stjamesdublin TSJCI 13th International Cancer Conference! @hematoclinicbcn

Honoured to see our phase 2 trial on Varnimcabtagene autoleucel for R/R B-ALL published in the March issue of @LancetHaem. A meaningful milestone for hospital-based innovation in cell therapy. Pleased to discuss the study with Julio Delgado in the accompanying podcast!

🚨New in Lancet Haematology: CART19-BE-02 reports the multicentre phase 2 trial of varnimcabtagene autoleucel (var-cel), a hospital-based, point-of-care CD19 CAR T for adults with R/R B-cell precursor ALL. sciencedirect.com/science/articl… 🔓Free access link: authors.elsevier.com/c/1mYpe_rV3GF9…

This Guidelines paper recommends prioritizing CAR T-cell therapy over bispecific antibodies or ADCs for eligible relapsed/refractory myeloma patients, as prior use of certain agents may reduce CAR T-cell effectiveness.  👉bit.ly/4rn5d5K

The current findings suggest that nonhematologic AIDs are prevalent in patients with chronic lymphocytic leukemia, and these patients have a better prognosis than patients who have autoimmune cytopenia. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert @miguel_argdtom @hematosantpau #leusm

Thrilled to share our new paper in Cancer on advances in CLL & Autoimmunity! 😊😊 Our comprehensive work dives into the clinical and immunologic alterations in these patients: epidemiology, prognosis, Th17/Treg cells... @gellc @hematosantpau @nilalbiol acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

CONGRESS | #ASH25 | PRESENTATION @gabriel_brisou @paoli_calmettes shares results from a comparative analysis of axi-cel vs liso-cel as 2L therapy in real-world patients with R/R LBCL in France. After PS-weighting, there was no significant difference in OS or PFS, however, axi-cel was associated with a higher incidence of ICANS, CRS, ICU transfers and NRM vs liso-cel. Follow our live feed for more updates: loom.ly/POS6cqk Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #lymphoma #lymsm #MedicalCongress

CONGRESS | #ASH25 | PRESENTATION Aina Oliver-Caldes shares findings from a real-world study of patients with RRMM treated with ARI0002h (cesnicabtagene autoleucel) (N = 123). ORR was 95%, MRG-neg rate was 91%. Any grade CRS was 63%; grade 3 CRS 1.6%. Grade 1-2 ICANS in 4% of patients, comparable to the pivotal clinical trial. Follow our live feed for more updates: loom.ly/Z6rsHq8 Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website. #mmsm #myeloma #MedicalCongress @ainitaoliver @hospitalclinic

📣SAVE THE DATE VII edición: "Aspectos prácticos en aplicación clínica de terapia Chimeric Antigen Receptor T-Cell (CAR-T)". 📅23-24 Oct 2025 📍Facultat de Medicina de la Universitat de Barcelona 🗣️Información e inscripciones: aulaclinic.com/cursos/1329/vi…

Drug development in MZL: caring for the forgotten child ⁦⁦@BloodPortfolio⁩ ⁦@c_thieblemont⁩ #Sylvain Carras ⁦@ComeBommier⁩ ashpublications.org/blood/article/…

🇪🇸 var-cel in R/R FL academic anti-CD19 CAR T-cells N = 27 CRS all grades 55%, grade 3+ 4% 3-y PFS 81% Worth reading @Hemasphere_EHA ! onlinelibrary.wiley.com/doi/10.1002/he…

Our academic CAR-T (var-cel or ARI0001) from ⁦@hematoclinicbcn⁩ achieved similar efficacy to other CD19-directed products with a negligible ICANS incidence! It’s been a reality for almost 30 pts, most pf them remaining in CR to date. Congrats! onlinelibrary.wiley.com/doi/10.1002/he…

I will also present the results of a study evaluating the use of cell-free cfDNA MRD in CLL together with my great colleague @miguel_argdtom No. 1430 #iwCLL2025

Check out our poster on the results of varnimcabtagene autoleucel (ARI0001) in CLL and Richter’s transformation! Poster no. 1905 #iwCLL2025

Sure it is! Apply now!

CONGRESS | #SOHO2025 | PRESENTATION @niravshahmd @MedicalCollege presents phase Ia results from the phase I NX-5948-301 trial of bexobrutideg (NX-5948) in patients with R/R CLL/SLL (N = 48). Bexobrutideg was well tolerated, and responses were rapid, with an ORR of 80.9%, a median time to first response of 1.87 months. Follow our live feed for more updates: loom.ly/rBZZxmc #leusm #lymsm #MedicalCongress

CONGRESS | #EHA2025 | POSTER Juan Du, Shanghai Changzheng Hospital, presents updated phase I results on 1L BCMA-CD19 dual CAR-T therapy in transplant-eligible high-risk NDMM (N=22). Median FU=37.1 months. High response rates: ORR and MRD-neg=100%; sCR=95%. Median DoR not reached. No Grade ≥3 CRS, ICANS or neurotoxicity. Follow our live feed for more updates: multiplemyelomahub.com/medical-inform… #myeloma #mmsm #MedicalCongress

Two patients had autoimmune hemolytic anemia that relapsed after CD19 CAR T-cell therapy but responded rapidly to BCMA-targeted T-cell–engager therapy with remission, minimal side effects, and hematologic improvement. Learn more: nej.md/3SM6S4V

Happy to present two posters about molecular MRD in AML at #EHA2025 in Milan. Check them out at today’s poster session!

Congrats to everyone! Especially to @LeppaSM and @JulioDelgadoHem @hematoclinicbcn